Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.35 |
| ▸ | GMNN | O75496 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22653991 | 1.00 | MEN1 (0.41) | MEN1KMT2ACYP3A4ALDH1A1TSHR | |
| SCHEMBL60120 | 0.86 | MEN1 (0.55) | MEN1KMT2ACYP3A4ALDH1A1TSHR | |
| SCHEMBL5209281 | 0.86 | TSHR (0.33) | MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL28709594 | 0.84 | MEN1 (0.57) | MEN1KMT2ACYP3A4ALDH1A1TSHR | |
| SCHEMBL4751225 | 0.82 | MEN1 (0.50) | MEN1KMT2ACYP3A4ALDH1A1TSHR | |
| SCHEMBL9331914 | 0.79 | CNR2 (0.39) | MEN1KMT2ACYP3A4SPHK2SPHK1 | |
| SCHEMBL2122857 | 0.76 | — | — | |
| SCHEMBL2122861 | 0.76 | — | — | |
| SCHEMBL7550524 | 0.74 | MEN1 (0.42) | MEN1KMT2ACYP3A4ALDH1A1TSHR | |
| SCHEMBL7550523 | 0.74 | MEN1 (0.42) | MEN1KMT2ACYP3A4ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024110905-A1 | ANTI-CEA ANTIBODY DRUG CONJUGATES AND METHODS OF USE | BEIGENE, LTD. (KY) | 2024-05-30 | — | — | WO | disclosed |
| CN-117878320-A | Binder for secondary battery, negative electrode for secondary battery comprising same, and lithium secondary battery comprising same | SK新技术株式会社 | 2024-04-12 | — | — | CN | disclosed |
| US-11931445-B2 | Composition comprising baicalin | L'OREAL (FR) | 2024-03-19 | — | — | US | disclosed |
| CN-116892036-A | Silver nanocluster catalyst for carbon dioxide conversion, gas diffusion electrode including the same, zero gap reactor including the same, and carbon dioxide conversion method using the same | 延世大学校产学协力团 | 2023-10-17 | — | — | CN | disclosed |
| EP-3820609-B1 | USE OF N-CHELATING RUTHENIUM COMPLEXES IN THE METATHESIS REACTION | APEIRON SYNTHESIS SA (PL) | 2023-06-28 | — | — | EP | disclosed |
| US-20230130617-A1 | PROCESS FOR IMPROVED OPIOID SYNTHESIS | RHODES TECHNOLOGIES (US) | 2023-04-27 | — | — | US | disclosed |
| EP-3558253-B1 | COMPOSITION COMPRISING BAICALIN | OREAL (FR) | 2022-12-28 | — | — | EP | disclosed |
| EP-4103578-A1 | NOVEL MRNA 5'-END CAP ANALOGS MODIFIED WITHIN PHOSPHATE RESIDUES, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | Uniwersytet Warszawski (PL) | 2022-12-21 | — | — | EP | disclosed |
| US-20210380619-A1 | Production method of cyclic compounds by olefin metathesis reaction and use of ruthenium catalysts in production of cyclic olefines by olefin metathesis reaction | UNIWERSYTET WARSZAWSKI (PL) | 2021-12-09 | — | — | US | disclosed |
| WO-2021162566-A1 | NOVEL MRNA 5'-END CAP ANALOGS MODIFIED WITHIN PHOSPHATE RESIDUES, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | UNIWERSYTET WARSZAWSKI (PL) | 2021-08-19 | — | — | WO | disclosed |
| WO-2005035500-A2 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-04-21 | — | — | WO | disclosed |
| EP-1519751-A2 | COMPOSITIONS COMPRISING PANTHETINE FOR THE TREATMENT OF DYSLIPIDEMIA | Esperion Therapeutics Inc. (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1487436-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | Signal Pharmaceuticals, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040116423-A1 | 5-Aryltetrazole compounds, compositions thereof, and uses therefor | INOTEK PHARMACEUTICALS CORPORATION | 2004-06-17 | — | — | US | disclosed |
| WO-2004029044-A1 | PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS | EURO-CELTIQUE, S.A. (LU) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004009563-A1 | 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR | INOTEK PHARMACEUTICALS CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20040019208-A1 | 5-Aryltetrazole Compounds, compositions thereof, and uses therefor | INOTEK PHARMACEUTICALS CORPORATION | 2004-01-29 | — | — | US | disclosed |
| WO-2004004774-A2 | COMPOSITIONS COMPRISING PANTHETINE FOR THE TREATMENT OF DYSLIPIDEMIA | ESPERION THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003075917-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931445-B2 | Composition comprising baicalin | KRT18, S100A6, DSG1 | MEN1 1651/4885KMT2A 4129/4885CYP3A4 2421/4885 |
| US-20210380619-A1 | Production method of cyclic compounds by olefin metathesis reaction and use of ruthenium catalysts in production of cyclic olefines by olefin metathesis reaction | COASY, POR, SQLE | MEN1 896/4885KMT2A 4647/4885CYP3A4 54/4885 |
| US-20230130617-A1 | PROCESS FOR IMPROVED OPIOID SYNTHESIS | OPRK1, OPRM1, OPRD1 | MEN1 4481/4885KMT2A 3486/4885CYP3A4 50/4885 |
| US-20040019208-A1 | 5-Aryltetrazole Compounds, compositions thereof, and uses therefor | CASP5, NLRP3, LITAF | MEN1 3398/4885KMT2A 3800/4885CYP3A4 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.